Seek Returns

GILD vs. ZTS: Gilead Sciences vs. Zoetis Stock Comparison

How do Gilead Sciences (GILD) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Gilead Sciences (GILD) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while ZTS is classified in Pharmaceuticals.

Company profile comparison for Gilead Sciences (GILD) and Zoetis (ZTS)
Profile ItemGILDZTS
NameGilead Sciences Inc.Zoetis Inc. Class A Common Stock
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization207.00 billion USD32.26 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJanuary 22, 1992February 1, 2013
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

GILD
ZTS
GSPC
Loading price history…
Gilead Sciences (GILD) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Gilead Sciences (GILD) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Gilead Sciences (GILD) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Gilead Sciences (GILD) and Zoetis (ZTS)
MetricGILDZTS
Total Return (1Y)45.69%-30.10%
Total Return (3Y, Annualized)35.30%-20.42%
Total Return (5Y, Annualized)25.00%-16.87%

Risk Profile

Drawdown History

GILD
ZTS
GSPC
Loading price history…
Gilead Sciences (GILD) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Gilead Sciences (GILD) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Gilead Sciences (GILD) and Zoetis (ZTS)
MetricGILDZTS
Volatility (1Y, Annualized)27.57%38.23%
Beta (5Y)0.360.66
Max Drawdown (5Y)-26.59%-70.45%
Avg. Volume (3M)5.98M4.65M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
GILD and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Gilead Sciences (GILD) and Zoetis (ZTS)
MetricGILDZTS
Sharpe Ratio (1Y)1.50-0.90
Sortino Ratio (1Y)2.48-1.10

Profitability

ROE (TTM)

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Zoetis (ZTS) reports 57.63%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max
109.18%
ZTS
57.63%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Zoetis (ZTS) reports 26.41%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS
26.41%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Gilead Sciences (GILD) at 42.43% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max
83.12%
ZTS
38.19%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Gilead Sciences (GILD) and Zoetis (ZTS)
MetricGILDZTS
ROE (TTM)-22.45%57.63%
ROA (TTM)13.47%14.87%
Net Margin (TTM)-12.46%26.41%
Operating Margin (TTM)42.43%38.19%
Gross Margin (TTM)79.95%71.65%

Growth

Revenue Growth

Both Gilead Sciences (GILD) at 2.39% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than Zoetis (ZTS) at 10.05%, which is closer to a typical peer reading.

Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Gilead Sciences (GILD) and Zoetis (ZTS)
MetricGILDZTS
Revenue Growth (YoY)2.39%2.28%
Revenue Growth (3Y CAGR)2.57%5.42%
EPS Growth (YoY)1,684.21%10.05%
EPS Growth (3Y CAGR)23.04%10.27%

Financial Strength

Current Ratio (MRQ)

Both Gilead Sciences (GILD) at 1.38 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ZTS
2.35
Min
0.10
Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Debt sits unusually high against shareholders’ equity for both Gilead Sciences (GILD) at 2.02 and Zoetis (ZTS) at 2.80 — each debt-to-equity ratio is above its industry benchmark range.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS
2.80
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Gilead Sciences (GILD) and Zoetis (ZTS)
MetricGILDZTS
Current Ratio (MRQ)1.382.35
Debt / Equity (MRQ)2.022.80
Net Debt / EBITDA1.251.92

Dividends

Dividend Yield (TTM)

Both Gilead Sciences (GILD) at 1.94% and Zoetis (ZTS) at 2.55% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS
2.55%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Gilead Sciences (GILD) at 43.46% and Zoetis (ZTS) at 35.24% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS
35.24%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Gilead Sciences (GILD) and Zoetis (ZTS)
MetricGILDZTS
Dividend Yield (TTM)1.94%2.55%
Dividend Payout Ratio (TTM)43.46%35.24%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Zoetis (ZTS) trades at 13.50 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max
85.34
Q3
43.46
Median
26.69
ZTS
13.50
Q1
13.30
Min
0.07
Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): GILD does not report P/E ratio, so it has no value marker; ZTS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max
58.18
Q3
25.77
Median
7.30
ZTS
3.40
Q1
3.01
Min
0.01
Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Zoetis (ZTS) at 9.80 sits in the upper P/B ratio quartile, and Gilead Sciences (GILD) at 15.88 prices even higher, above its industry range.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max
13.53
ZTS
9.80
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Gilead Sciences (GILD) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Gilead Sciences (GILD) and Zoetis (ZTS)
MetricGILDZTS
P/E Ratio (TTM)--13.50
P/S Ratio (TTM)6.683.40
P/B Ratio (MRQ)15.889.80
Free Cash Flow Yield (TTM)5.16%6.36%